International Journal of Drug Delivery Technology
Volume 14, Issue 2

To Synthesize and Characterize Metabolite Enalapril: PKPD and Toxicity Predictions by Computational Approaches

Parag Pathade1*, Vinod Bairagi1, Shraddha Vaishnav1, Shraddha Dingare2

1Department of Pharmaceutical Chemistry, KBHSS Trust’s Institute of Pharmacy, Nashik, Maharashtra, India.

2Department of Pharmaceutics, Lokmanya Tilak Institute of Pharmaceutical Sciences, Pune, Maharashtra, India.

Received: 10th January, 2024; Revised: 19th March, 2024; Accepted: 07th May, 2024; Available Online: 25th June, 2024 

ABSTRACT

Enalapril is a prodrug that facilitates the transformation of angiotensin I to angiotensin II, an ingredient that brings constriction of blood vessels by action of the enzyme angiotensin-converting enzyme (ACE). Reversed-phase high-performance liquid chromatography (RP-HPLC) method is the focus of this work, which also includes its characterization, optimization, and synthesis. The objective is to correctly, precisely, and sensitively determine both enalapril and its synthesized metabolite, enalaprilat, when present as an impurity. The paper also forecasts the ADME and toxicity characteristics of ENLP by utilizing several ADME databases, including SWISS ADME and molesoft. The laboratory synthesized enalaprilat, the metabolite derived from enalapril, and characterized. The Kinetex C18 stationary phase was employed in the analytical approach. Flow rate was 1.0 mL/min, and the injection volume was 20 µL. With a wavelength of 244 nm, the run lasted for 10 minutes. The mobile phase used was an 80% acetonitrile: 20% pH 3 phosphate buffer. The HPLC technique validation, which involved the identification of the enalapril metabolite, followed the parameters outlined in ICH Q2B (R1). The analysis exhibited a range of accuracy and precision between 98.75 and 102.5% for all substances being tested. This approach is appropriate for identifying and measuring the metabolite in enalapril bulk or formulations. The method for assessing enalaprilat in biological fluids has the potential to be further refined and applied in clinical and bioequivalence research. The study furthermore presents an evaluation of toxicity utilizing computational methods such as the Swiss tool, with the objective of aiming to mitigate potential risks.

Keywords: Enalapril, Enalaprilat, RP-HPLC, ADME database.

International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.2.52

How to cite this article: Pathade P, Bairagi V, Vaishnav S, Dingare S. To Synthesize and Characterize Metabolite Enalapril: PKPD and Toxicity Predictions by Computational Approaches. International Journal of Drug Delivery Technology. 2024;14(2):948-954.

REFERENCES

  1. Kar S, Leszczynski J. Recent advances of computational modeling for predicting drug metabolism: a Current Drug Metabolism. 2017 Dec 1;18(12):1106-22.
  2. Tabacova SA, Kimmel Enalapril: pharmacokinetic/dynamic inferences for comparative developmental toxicity: A review. Reproductive Toxicology. 2001 Sep 1;15(5):467-78.
  3. Shioya H, Shimojo M, Kawahara Determination of enalapril and its active metabolite enalaprilat in plasma and urine by gas chromatography/mass spectrometry. Biomedical Chromatography. 1992 Mar;6(2):59-62.
  4. Worland PJ, Jarrott B. Radioimmunoassay for the quantitation of lisinopril and Journal of pharmaceutical sciences. 1986 May;75(5):512-6.
  5. Thongnopnua P, Poeaknapo C. High-performance liquid chromatographic determination of enalapril in human plasma by enzyme kinetic analytical Journal of pharmaceutical and biomedical analysis. 2005 Apr 1;37(4):763-9.
  6. Deore S, Kachave R, Gholap P, Mahajan K, Tare Computational Identification of Methionyl-tRNASynthetase Inhibitors for Brucella melitensis: A Hybrid of Ligand-based Classic 3-Point Pharmacophore Screening and Structure Cavity Guided Blind Docking Approach. International Journal of Pharmaceutical Quality Assurance. 2023;14(4):1151-7.
  7. Gu Q, Chen X, Zhong D, Wang Simultaneous determination of enalapril and enalaprilat in human plasma by liquid chromatography–tandem mass spectrometry. Journal of Chromatography B. 2004 Dec 25;813(1-2):337-42.
  8. Lee J, Son J, Lee M, Lee KT, Kim Simultaneous quantitation of enalapril and enalaprilat in human plasma by 96‐well solid‐ phase extraction and liquid chromatography/tandem mass spectrometry. Rapid communications in mass spectrometry. 2003 Jun 15;17(11):1157-62.
  9. Pund S, Nalawade S, Rajurkar V, Jayatpal S, Deshmukh N, Tare A brief review on recent advances in reverse phase HPLC.Multidisciplinary Reviews. 2024 Jan 18;7(4):2024072-.
  10. Guidelines ICH. Validation of analytical procedures: text and methodology. Q2 (R1). 2005 Nov;1(20):05.
  11. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific reports. 2017 Mar 3;7(1):42717.
  12. Shakir RM, Saoud SA, Jasim HS, Hussain DF. Synthesis, Antioxidant Activity and Molecular Docking Study of 1,2,4-Triazole and Their Corresponding Fused Rings Containing 2-Methylphenol. International Journal of Drug Delivery Technology. 2021;11(2):501-511.
  13. Adil B, Shahar S, Amran SI, Omar MSS, Naser MA. Computational Investigation of the Impact of the Ghrelin Hormone Gene Variation (R51q) on the Hormone-receptor Binding International Journal of Pharmaceutical Quality Assurance. 2023;14(1):196-202.
  14. Mandal M, Mandal S. MM/GB (PB) SA integrated with molecular docking and ADMET approach to inhibit the fat- mass-and-obesity-associated protein using bioactive compounds derived from food plants used in traditional Chinese medicine. Pharmacological Research-Modern Chinese Medicine. 2024 Jun 1;11:100435.
  15. Tare H, Vaidya V, Fulmali S, Jadhao S, Wankhade M, Bhise Transcriptomic Insight and Structural Integration: Repositioning FDA-Approved Methotrexate Derivative for Precision Therapy in Lung Cancer through Drug-Drug Similarity Analysis and Cavity-Guided Blind Docking. International Research Journal of Multidisciplinary Scope (IRJMS), 2024; 5(1): 631-639.